China-based Clover Biopharmaceuticals Ltd (Clover; HKG: 2197) has announced the establishment of a commercial partnership with Keyuan Xinhai (Beijing) Medical Products Trading Co., Ltd (Kyuan Trade). The strategic alliance aims to prepare for the commercial launch of AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged 3 years and older in China, with an expected launch in the second half of 2023.
Kyuan Trade’s Extensive Distribution Network
Kyuan Trade boasts an extensive distribution network that covers 31 provinces, municipalities, and autonomous regions, as well as over 2,000 district and county centers for disease control. This partnership will leverage Kyuan Trade’s network to complement Clover’s established and growing commercial capabilities, ensuring broad access to AdimFlu-S (QIS) across China.
Maximizing Access to AdimFlu-S (QIS)
The collaboration between Clover and Kyuan Trade is set to maximize the distribution and accessibility of AdimFlu-S (QIS), providing a significant public health benefit by offering a comprehensive influenza protection option to a wider population. This move underscores Clover’s commitment to enhancing vaccine availability and public health infrastructure in China.-Fineline Info & Tech
